Bevacizumab an improvement on standard therapy in colorectal cancer

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1399, 2003-01, pp. : 7-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bevacizumab in colorectal cancer: profile report

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 21, Iss. 5, 2005-05 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite

WTP high for raltitrexed vs standard therapy in colorectal cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 380, 2002-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Vatalanib gives standard first-line therapy a boost in colorectal cancer

By  

Inpharma, Vol. 1, Iss. 1471, 2005-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

WTP high for raltitrexed vs standard therapy in colorectal cancer

By  

Inpharma, Vol. 1, Iss. 1355, 2002-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer

By Yamada Yasuhide  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1690-1696

Springer Publishing Company

Access to resources Recommend Favorite